![]() It is the first drug to be licensed for the condition in nearly two decades, and the first to be based on the contentious “amyloid hypothesis” of the disease. The amyloid-beta antibody aducanumab was issued a “negative trend vote” by European regulators, announced its developer Biogen in a statement on November 17.Īducanumab’s rollercoaster development reached an exhilarating peak earlier this year when it was approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |